Bengaluru, July 26 -- Diagnostics and online pharmacy platform Tata 1mg is doubling down on its business-to-business (B2B) offerings, which bolstered growth in FY25, a top executive told Mint. The enterprise business accounts for 30% of the company's revenue and is expected to grow substantially by the end of the current fiscal year, Gaurav Agarwal, co-founder of Tata 1mg, said in an interview. "Our enterprise business is growing very fast-almost 100% year on year. We see tremendous growth opportunities in corporate programmes, especially in diagnostics." Tata 1mg's B2B segment includes the sale of selling healthcare plans to its corporate clientele. The company has been expanding its diagnostics lab centres and increasing the availability ...